Agenus secured up to $340 million in a private placement to fund a pivotal Phase 3 trial of its immunotherapy combination in colon cancer, sending shares surging 111% on Monday as investors embraced the company’s strategic shift toward an earlier treatment setting.
The financing includes $85 million in upfront gross proceeds, with an additional $255 million available through the full exercise of purchase warrants. Commodore Capital led the oversubscribed round, joined by RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. Agenus expects the funding to support operations through the end of 2031.
The proceeds will advance ROBBIN, a planned registrational Phase 3 trial evaluating neoadjuvant botensilimab and balstilimab (BOT+BAL) in previously untreated, high-risk Stage II and Stage III microsatellite-stable (MSS) colon cancer. The trial will enroll 850 patients globally and compare the combination followed by standard of care against standard of care alone, with event-free survival as the primary endpoint. Agenus expects the first patient in the first quarter of 2027, with interim pathologic response data anticipated in the second half of 2027.
The shift to the neoadjuvant setting—treating patients before surgery rather than after progression—reflects emerging clinical evidence from smaller trials. Two Phase 2 studies, NEST and UNICORN, showed pathologic complete responses in approximately 30% of patients and major pathologic responses in 35% to 40%, with all treated patients remaining disease-free at median follow-ups of nine to 18 months, according to Agenus.
The funding announcement came just one week after Agenus released landmark three-year survival data from a Phase 1b study in refractory MSS metastatic colorectal cancer. The fully enrolled 123-patient cohort demonstrated a 21.2-month median overall survival and a 33% three-year overall survival rate, with the survival curve plateauing beyond two years. In the heavily pretreated population, available standard therapies have historically reported median overall survival of 10–14 months, making the durability of response notable in a setting where few patients typically survive to later timepoints.
As part of the strategic refocus, Agenus will discontinue financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer. The company is prioritizing the neoadjuvant opportunity, which targets a market Agenus estimates at more than $7 billion annually in the United States for high-risk Stage II and Stage III MSS colon cancer, with no new curative-intent therapies approved in that setting in more than two decades.
The company has aligned key elements of the ROBBIN trial design with the U.S. Food and Drug Administration, including the patient population, treatment regimen, control arm, endpoint, and interim analysis plan. Interim event-free survival analysis is expected in the second half of 2029, with final analysis anticipated in the second half of 2030.
Sources
- Proactive Investors — Agenus shares surge announcement, $340M private placement, ROBBIN trial details, market opportunity, and stock move
- Benzinga — Stock surge of 111% confirmation and colorectal cancer data context
- Agenus Investor Relations — Three-year survival data, 21.2-month median OS, 33% three-year OS rate, Phase 1b trial details, and safety profile
- RTTNews — BATTMAN Phase 3 trial discontinuation announcement
- StreetInsider — Funding details and trial design confirmation
